Brief: Felzartamab Granted Breakthrough Therapy Designation by U.S. FDA for Primary Membranous Nephropathy

NovaBridge Biosciences

02/11/2023 12:55

Nov 2 (Reuters) - I-Mab  IMAB.O :
    * FELZARTAMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY
U.S.
FOOD AND DRUG ADMINISTRATION (FDA) FOR PRIMARY MEMBRANOUS
NEPHROPATHY (PMN)
    * I-MAB - FULL DEVELOPMENT,COMMERCIALIZATION RIGHTS OF
FELZARTAMAB
IN GREATER CHINA FOR INDICATIONS, WITH PHASE 3 MULTIPLE MYELOMA
DATA EXPECTED IN 2024

Source text for Eikon:  ID:nPn7gmhLja 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))